Evaluation of amyloid change as a surrogate for cognitive decline: demonstration in individual-level data from the A4 study of solanezumab
{{output}}
Background: Differential amyloid change has served as a surrogate outcome in Alzheimer's disease trials, allowing accelerated approval of aducanumab and lecanemab. Individual-level data from the A4 study support the demonstratio... ...
